PMID- 28117883
OWN - NLM
STAT- MEDLINE
DCOM- 20170531
LR  - 20180301
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 123
IP  - 8
DP  - 2017 Apr 15
TI  - Identifying and targeting cancer stem cells in the treatment of gastric cancer.
PG  - 1303-1312
LID - 10.1002/cncr.30538 [doi]
AB  - Current treatment regimens for gastric cancer are not adequate. Cancer stem cells
      (CSCs) may be a key driving factor for growth and metastasis of this tumor type. 
      In contrast to the conventional clonal evolution hypothesis, CSCs can initiate
      tumor formation, self-renew, and differentiate into tumor-propagating cells.
      Because gastric cancer can originate from CSCs, it is necessary to review current
      targets of signaling pathways for CSCs in gastric cancer that are being studied
      in clinical trials. These pathways are known to regulate the self-renewal and
      differentiation process in gastric CSCs. A better understanding of the clinical
      results of trials that target gastric CSCs will lead to better outcomes for
      patients with gastric cancer. Cancer 2017;123:1303-1312. (c) 2017 The Authors.
      Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
      This is an open access article under the terms of the Creative Commons
      Attribution NonCommercial License, which permits use, distribution and
      reproduction in any medium, provided the original work is properly cited and is
      not used for commercial purposes.
CI  - (c) 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of
      American Cancer Society.
FAU - Bekaii-Saab, Tanios
AU  - Bekaii-Saab T
AD  - Gastrointestinal Cancer Program, Mayo Clinic Cancer Center, Phoenix, Arizona.
AD  - Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona.
FAU - El-Rayes, Bassel
AU  - El-Rayes B
AD  - Department of Hematology and Medical Oncology, Emory School of Medicine, Atlanta,
      Georgia.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
DEP - 20170124
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Biomarkers, Tumor
MH  - Clinical Trials as Topic
MH  - Disease Management
MH  - Drug Discovery
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Neoplastic Stem Cells/*drug effects/metabolism
MH  - Practice Guidelines as Topic
MH  - Risk Factors
MH  - Signal Transduction/drug effects
MH  - Stomach Neoplasms/diagnosis/*drug therapy/epidemiology
MH  - Treatment Outcome
PMC - PMC5412889
OTO - NOTNLM
OT  - *cancer stem cells
OT  - *clinical trials
OT  - *gastric cancer
OT  - *napabucasin
OT  - *targeted therapy
OT  - *vismodeqib
EDAT- 2017/01/25 06:00
MHDA- 2017/06/01 06:00
CRDT- 2017/01/25 06:00
PHST- 2016/09/02 00:00 [received]
PHST- 2016/11/11 00:00 [revised]
PHST- 2016/12/01 00:00 [accepted]
PHST- 2017/01/25 06:00 [pubmed]
PHST- 2017/06/01 06:00 [medline]
PHST- 2017/01/25 06:00 [entrez]
AID - 10.1002/cncr.30538 [doi]
PST - ppublish
SO  - Cancer. 2017 Apr 15;123(8):1303-1312. doi: 10.1002/cncr.30538. Epub 2017 Jan 24.